Evolus Inc (EOLS) Actualités

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of...

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the...

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten...

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

Generated $0.8M of Cash from Operating Activities in Q4 2023 Recorded Lowest Quarter of Non-GAAP Operating Loss Since Inception, Non-GAAP...

Evolus Announces Results from European Head-to-Head Filler Trial

Evolus dermal filler product (Evolysse™/Estyme® Lift) demonstrates statistical superiority at 3 and 6 months compared to Restylane-L with...

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...